# Radj Gervais

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/radj-gervais/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,034 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 42 |
| i10-index | 88 |
| OpenAlex ID | https://openalex.org/A5103479672 |
| Works | 160 |

## Researcher papers

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy](https://scholariq.org/papers/randomized-phase-iii-trial-of-pemetrexed-versus-docetaxel-in-patients-with-non/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study](https://scholariq.org/papers/bevacizumab-in-patients-with-nonsquamous-non-small-cell-lung-cancer-and/)
- [Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002](https://scholariq.org/papers/noninvasive-diagnosis-of-actionable-mutations-by-deep-sequencing-of-circulating/)
- [A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics](https://scholariq.org/papers/a-brief-report-of-transformation-from-nsclc-to-sclc-molecular-and-therapeutic/)
- [Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial](https://scholariq.org/papers/afatinib-beyond-progression-in-patients-with-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.